No clinically substantial dissimilarities from the pharmacokinetics of midazolam (CYP3A4 substrate) or its metabolite 1-hydroxymidazolam were being noticed when employed concomitantly with solitary or several doses of lumateperone in people with schizophrenia.Antipsychotic medications have brought about metabolic modifications, which include hyperg